

**CANADIAN SOCIETY OF TRANSPLANTATION
SOCIÉTÉ CANADIENNE DE TRANSPLANTATION
FINAL PROGRAM-PROGRAMME FINAL
du 13 mars au 16 mars / March 13 to March 16, 2013**

WEDNESDAY, MARCH 13 / LE MERCREDI 13 MARS 2013

0800-1730	CST Board Meeting (closed)	<i>Lefroy Room</i>
0700-1830	CST Research FITS	<i>Pipestone A & B</i>
0700-0745	Breakfast	
0745-0800	Welcome and Introduction Chair: Dr. Patricia Birk, Chair, CST Education Committee	
0800-0845	Presentation #1: (40 min + 5 min Q&A) <i>Moderator: Kimberly Young</i> State of the Art Lecture: Translating Omics: 'I want to do a Clinical Trial: What's Involved?' Dr. Julie Ho (<i>Winnipeg, MB</i>)	
0845-0945	Presentation #2: (55 min + 5 min Q&A) <i>Moderator: Dr. Patricia Birk</i> The Art (and Science) of Grant and Abstract Writing Dr. Lori West (<i>Edmonton, AB</i>)	
0945-1015	Coffee Break	
1015-1100	Presentation #3: (40 min + 5 min Q&A) <i>Moderator: Dr. Janice Bissonnette</i> Academic Mentoring: What, Why and How? Dr. Marie-Josée Hébert (<i>University of Montréal</i>)	
1100-1200	Trainees Presentations x 5 (7 min + 3min Q&A) <i>Moderator: Dr. Patricia Birk and Kimberly Young</i>	
	1100 Recipient Pre-Operative Regulatory T Cell Function: A Predictor of Acute Kidney Injury After Kidney Transplantation – Minh-Tri Nguyen (<i>Montréal, QC</i>) (Abstract # 2448)	
	1110 Correlation of HLA Alloepitopes with the Development of De Novo Donor Specific Antibodies After Renal Transplantation – Chris Weibe (<i>Winnipeg, MB</i>) (Abstract # 2427)	
	1120 A phospho-specific flow cytometry assay to define the role of the inhibitory molecule CD22 on infant CD27+IgM+ B-cells, containing ABO antigen-specific antibody-secreting cells, in the down-regulation of B-cell signaling - Kimberly Derkatz (<i>Edmonton, AB</i>) (Abstract # 2505)	
	1130 Right Ventricular Distension In Donor Hearts Following Cardiocirculatory Death: Implications For Post-Transplant Function - Christopher White (<i>Winnipeg, MB</i>) (Abstract # 2480)	
	1140 Autoantibodies and Rejection After Heart Transplantation: Profiling With Antigen Microarrays – Andrzej Chruscinski (<i>Toronto, ON</i>) (Abstract # 2419)	
1200-1300	Lunch & Networking	<i>Larch Lounge</i>
1300-1400	Trainees Presentations x 5 (7 min + 3min Q&A) <i>Moderator: Drs. Patricia Birk and Janice Bissonnette</i>	
	1300 Pre-Kidney Transplant Biopsy In Expanded Criteria Donors Do Not Correlate With Outcomes – Sinziana Dumitra (<i>Montréal, QC</i>) (Abstract # 2462)	
	1310 Inferior Survival In Liver Transplant Patients With Hepatocellular Carcinoma Receiving Donation After Cardiac Death Liver Allografts – Kris Croome (<i>London, ON</i>) (Abstract # 2438)	

	<p>1320 Predictors of Reversibility of Renal Function After Acute Rejection and Its Impact On Graft Survival In Kidney Transplant Recipients – <i>Emilie Trinh (Montréal, QC) (Abstract # 2446)</i></p> <p>1330 Dichotomous T-Cell Repopulation After Anti-Thymocyte Globulin Induction Therapy In High Immunological Risk and DCD Renal Transplant Recipients – <i>Neal Rowe (London, ON) (Abstract # 2482)</i></p> <p>1340 First Canadian Experience In Pediatric En-Bloc Renal Allograft Donation After Cardiac Death – <i>Marie Dion (London, ON) (Abstract # 2494)</i></p>	
1400-1500	<p>Presentation #4: (55 min + 5 min Q&A) <i>Moderator: Kimberly Young</i></p> <p>How Do I Get My Paper Published (in a Reputable Transplant Journal)? Speaker: Dr. John Gill (<i>Vancouver, BC</i>)</p>	
1500-1530	Coffee Break	
1530-1700	<p>Workshop: <i>Moderator: Dr. Janice Bissonnette</i></p> <p>Designing a CV and Teaching Dossier Dr. Julian Midgley (<i>Calgary, AB</i>)</p>	
1700-1715	<p>Closing Remarks Dr. Patricia Birk</p>	<i>Larch Lounge</i>
1715-1830	<p>Awards Reception All</p>	
1400-1900	REGISTRATION – INSCRIPTION	<i>Alpine Gallery</i>
1800-2130	CST Canadian Pediatric Group Meeting	<i>Alpine Room</i>
1745-1830	<p>Welcome and Dinner Véronique Phan</p>	
1830-1845	Trainee abstract award winner - Ying Ling	
1845-1915	<p>'The Canadian National Transplant Research Program: an investment in transformative research for patients' – Key Note Speaker - Lori West (<i>Edmonton, AB</i>)</p>	
1915-2000	<p>Positive Study – Seema Mital (<i>Toronto, ON</i>), Beth Foster (<i>Montreal, QC</i>), Simon Urschel (<i>Winnipeg, MB</i>)</p>	
2000-2130	Business Meeting and Elections – Veronique Phan	

THURSDAY, MARCH 14 / LE JEUDI 14 MARS 2013

0700-1600	REGISTRATION – INSCRIPTION	Alpine Gallery
0700-0815	<i>Breakfast on own</i>	
0700-0800 0700-0800	BK: KIDNI Clinical Trial Meeting (<i>closed</i>) CNTRP Meeting (<i>closed</i>)	Saddleback Room Sunroom
0830-1200	CST GROUP MEETINGS	
	Canadian Liver Transplant Network (0800-1615)	Pipestone
	Canadian Cardiac Transplant Network	Lakeshore Room
	Canadian Lung Transplant Group	Louise Room
	Canadian Kidney Transplant Group & HLA Group	Mount Temple A & B
	Canadian Pancreas Group	Agnes Room
	Canadian Donation Group	Mollison Room
1000-1030	COFFEE BREAK (<i>in each respective Group's Meeting room</i>)	
1230-1430	Canadian HLA Group (<i>closed</i>)	Mount Temple A & B
1200-1300	Lunch on own	
1230-1530	CST High Risk Donor Guidelines Development Meeting (<i>Closed</i>)	Alpine Room
1300-1600	CCTN Education Session Focus: Mechanical Circulatory Support In End-Stage Heart Failure	Plain of Six Glaciers Room
1300-1330	Update on RV Support: Experience With R Sided Impella - Dr. Darren Freed	
1330-1400	VAD Options for Failing Fontans and Uni-Ventricular Hearts - Dr. Osami Honjo	
1430-1500	Quality of Life in VAD Patients: Qualitative Review - Dr. Jane MacIver	
1500-1545	Interactive VAD Case Presentations - Trainees	
1600-1830	CST OPENING PLENARY SESSION I: "Should The Organ Fit The Immune System – Or Vice Versa?" <i>Chairs: Drs. Kathryn Tinckam and Deepali Kumar</i>	Mount Temple A & B
1600-1615	Opening Remarks - Dr. Tom Blydt-Hansen, <i>CST President</i>	
1615-1700	Build the Organ to Fit the Immune System – <i>Dr. Shaf Keshavjee</i>	
1700-1745	Chimerism for the Induction of Tolerance: Mechanisms and New Directions - Dr. Megan Sykes, (<i>Columbia University</i>) <i>Objectives: To understand the mechanisms and methods for achieving tolerance in transplantation. To understand the use of mixed chimerism for tolerance induction. To understand the role of regulatory T Cell in achieving tolerance and reversing autoimmunity through mixed chimerism.</i>	
1745-1830	Therapeutic Use of Treg Cells - Dr. Megan Levings, (<i>University of BC</i>) <i>Objectives: Know what T regulatory cells are and how they can be applied to transplantation. Appreciate the difficulties in obtaining human T regulatory cells for therapy. Know about some of the signaling pathways that are essential for controlling the function of T regulatory cells.</i>	
1830- 1930	EXHIBITS OPEN & RECEPTION	Mount Temple C
1900- 1945	RECEPTION WITH SPONSORS (<i>Invitation Only</i>)	Mollison Room
1930 - ON	SOCIAL EVENING - <i>Ticketed Dinner at Brewster's Barn with Family Entertainment</i> <i>Short 10 min. walk to Brewster's Barn; signs/guides along the way from the hotel</i>	Brewster's Barn
1900-2000	Guests/children arrive – (storytelling, musical performance and magic), cash bar	
2000	Dinner – cash bar	
2100	Dancing – (DJ/ Entertainment), cash bar	
2400	Last guests depart	

FRIDAY, MARCH 15 / LE VENDREDI 15 MARS 2013

0630-1615	REGISTRATION – INSCRIPTION	<i>Alpine Gallery</i>
0630-0745	SUNRISE SYMPOSIUM 0630-0700 Breakfast 0700-0745 Symposium - The Adherence Dilemma <i>Chair: Dr. Tom Blydt-Hansen</i> Using Adherence Assessment to Inform Clinical Decision Making – <i>Dr. Ahna Pai (Cincinnati, OH)</i> <i>Objectives: To discuss metrics of adherence, their utility and limitations; to review association of traditional adherence metrics to transplant outcomes; to discuss if non-adherence can or should be used to deny transplant.</i> Reduced Transplant Survival Rates During Emerging Adulthood: What is the Evidence and Can It Be Improved? – <i>Dr. Beth Foster (Montréal, QC)</i>	<i>Mount Temple A & B</i>
0700 -1000	SET-UP POSTERS (odd numbers)	<i>Heritage Hall</i>
0700-ON	EXHIBITS CONTINUE	<i>Mount Temple C</i>
0800-1230	<u>CST PLENARY SESSION II: Concurrent Organ Specific Sessions</u>	
	<u>CST-CSN Joint sponsored Kidney Pancreas Transplant Session</u> <i>Opening Remarks Drs. John Gill and Tom Blydt-Hansen</i>	<i>Mount Temple A & B</i>
	The Inherited Complement Disorders – New Insights and Implications for Transplant <i>Chairs: Drs. Sacha de Serres and Leroy Storsley</i>	
	0800-0815 Introduction - Dr. Dan Cattran, (University Health Network, University of Toronto) <i>Review the historical aspects of this disease process, the evolution of the mechanistic understanding of the disease in native and transplant kidneys, and the current recognition of the major variants.</i>	
	0815-0845 The New MPGN Pathology – Dr. Sanjeev Sethi, (Mayo Clinic, Rochester, MN) <i>Discuss the development of the MPGN pattern of injury, the approach to the pathologic examination to classify complement mediated disease and other etiologies, and advances in the pathologic diagnostic techniques for describing these processes.</i>	
	0845-0915 Complement Pathways and Mechanisms of Disease – Dr. Christoph Licht, (Hospital for Sick Children, University of Toronto) <i>Discuss the biology and genetics of the inherited complement disorders, the development of the clinical syndromes, the complement regulatory pathways, and implications for patients with native kidney disease and kidney transplant.</i>	
	0915-0945 Clinical Spectrum of Disease and Implications for Treatment and Transplant - Dr. Dan Cattran, (University Health Network, University of Toronto) <i>Review natural history of these and related disorders in the context of therapeutic strategies, options for individualized treatments based upon greater understanding of the genetic basis and pathologic features of disease.</i>	
	0945-1000 Questions and Panel Discussion	
	1000-1100 COFFEE AMONGST THE POSTERS – Authors Present – (Odd Numbers)	<i>Mount Temple C & Heritage Hall</i>
	1100-1230 Abstract presentations <i>Chairs: Drs. Jean-François Cailhier and Lorraine Bell</i> 1100 Older Living-donor Kidney Transplantation vs. Dialysis and Standard Criteria Deceased Donor Transplantation: A Decision Analysis – Ruth Sapir-Pichdze * (Toronto, ON) (Abstract # 2466)	

- 1110** Probability Of A Positive AHG-CDC Crossmatch Is Determined By The Number, Strength And Specificity Of Anti-HLA Antibodies – James Lan (*Vancouver, BC*) (Abstract #2489)
- 1120** Predictors Of Reversibility Of Renal Function After Acute Rejection and Its Impact On Graft Survival In Kidney Transplant Recipients - Emilie Trinh (*Montréal, QC*) (Abstract # 2446)
- 1130** Conversion From Twice-Daily (Prograf®) To Once-Daily (Advagraf®) Tacrolimus Formulation In Stable Pediatric Kidney Transplant Recipients: A Comparative Pharmacokinetic Study –Anne-Laure Lapeyraque (*Montréal, QC*) (Abstract # 2426)
- 1140** Pre-Kidney Transplant Biopsy in Expanded Criteria Donors do not Correlate with Outcomes – Sinziana Dumitra (*Montréal, QC*) (Abstract # 2462)
- 1150** ABO Incompatible Kidney Transplantation Using ABO Immunoabsorption Column – Jeff Zaltzman (*Toronto, ON*) (Abstract # 2418)
- 1200** Correlation of HLA Alloepitopes with the Development of De Novo Donor Specific Antibodies After Renal Transplantation – Chris Wiebe (*Winnipeg, MB*) (Abstract # 2427)
- 1210** The caspase inhibitor IDN-6556 reduces injury due to cold ischemia and reperfusion in kidney transplant – Boris Gala-Lopez (*Edmonton, AB*) (Abstract # 2465)
- 1220** Influence Of Activating Killer Immunoglobulin-Like Receptors Of Natural Killer Cells Among Renal Transplant Recipients On Protection Against Cytomegalovirus Infection/Reactivation – Poonam Dharmani (*Calgary, AB*) (Abstract # 2477)

CST-CCTN Cardiac Transplant Session

Lakeshore Room

FOCUS – Antibodies and Graft Vasculopathy

Chairs: Drs. Mike McDonald and Simon Urschel

0800-0840

C1Q and Post-Transplant Outcomes

Dr. Hannah Valantine (*Stanford University*)

0840-1000

CST-CCTN Transplant Abstract Presentations

- 0840** Prevention Allograft Rejection In Heart Transplantation Through Concurrent Gene Silencing Of TLR And Kinase Signaling Pathways – Xusheng Zhang (*London, ON*) (Abstract # 2471)
- 0850** Right Ventricular Distension In Donor Hearts Following Cardiocirculatory Death: Implications For Post-Transplant Function – Christopher White (*Winnipeg, MB*) (Abstract # 2480)
- 0900** A Phospho-Specific Flow Cytometry Assay To Define The Role Of The Inhibitory Molecule CD22 On Infant CD27+Igm+ B-Cells, Containing ABO Antigen-Specific Antibody-Secreting Cells, In The Down-Regulation Of B-Cell Signaling – Kimberly Derkatz (*Edmonton, AB*) (Abstract # 2505)
- 0910** Autoantibodies and Rejection After Heart Transplantation: Profiling with Antigen Microarrays - Andrzej Chruscinski (*Toronto, ON*) (Abstract # 2419)
- 0920** Pharmacogenetic Variability in Response to Amlodipine in Hypertensive Pediatric Cardiac Transplant Recipients – Seema Mital (*Toronto, ON*) (Abstract # 2444)
- 0930** MFG-E8 Release By Apoptotic Endothelial Cell Microenvironment Reprograms Macrophages Into Pro-Fibrotic Cells – Marie-Joëlle Brissette (*Montréal, QC*) (Abstract # 2504)
- 0940** CD1d+CD5+ B cells Produce Interleukin-10 and have a Regulatory Capacity in Children: Impact on Graft Acceptance? – Ying Ling (*Edmonton, AB*) (Abstract # 2487)
- 0950** Resveratrol Attenuates Stimulated T-Cells Activation and Proliferation: A Novel Adjunct Therapy Against Cellular Rejection in Cardiac Transplantation – Jayan Nagendran (*Edmonton, AB*) (Abstract # 2450)

1000-1100	COFFEE AMONGST THE POSTERS – Authors Present – (Odd Numbers)	<i>Mount Temple C & Heritage Hall</i>
1100-1130	Evolution of HLA Testing Dr. Kathryn Tinckam	
1130-1150	Pathology of AMR: Relevance of C3d, C4d and FC Staining Dr. Michael Mengel	
1150-1210	Therapeutic Options for Antibody Mediated Graft Impairment Dr. Simon Urschel	
1210-1245	Do mTOR Inhibitors Impact Development or Progression of CAV? Dr. Howard Eisen	
1245-1300	CCTN Trainee Award Presentation Feedback and Evaluation	
<u>Lung Transplant Session</u>		<i>Beehive Room</i>
<i>Chair: Dr. Dale Lien</i>		
0900-1000	Keynote Speaker The Development of Lung Transplantation at the University of Toronto: Experiences and Anecdotes - Dr. Michael Hutcheon (<i>Toronto, ON</i>) <i>2013 Recipient of the Joel S. Cooper Award for outstanding contribution to lung transplantation in Canada.</i> <i>Objectives: Review evolution of lung transplant with respect to recipient age. Review experience with Burkholderia cenocepacia.</i>	
1000-1100	COFFEE AMONGST THE POSTERS – Authors Present – (Odd Numbers)	<i>Heritage Hall</i>
1100-1200	Abstract Presentations	
1100	Specific Inhibition Of Protein Kinase C-D Reduces Ischemia-Reperfusion Induced Lung Injury In Vivo - Jinbo Zhao (<i>Toronto, ON</i>) (<i>Abstract # 2415</i>)	
1110	Ten Years Experience With Extra Corporeal Life Support For Adult Respiratory Failure: Evolution Of Indications, Techniques And Outcomes -Marcelo Cypel (<i>Toronto, ON</i>) (<i>Abstract # 2496</i>)	
1120	Discovery of mRNA Biomarkers Predicting Donor Lung Failure – Ricardo Zamel (<i>Toronto, ON</i>) (<i>Abstract #2498</i>)	
1130	Damage-Associated Molecular Pattern Molecules In Human Chronic Lung Allograft Dysfunction: Potential Markers For Biologic Subtyping – Tomohito Saito (<i>Toronto, ON</i>) (<i>Abstract # 2502</i>)	
1140	Proteinuria And Chronic Kidney Disease In Lung Transplant Recipients – Nilu Partovi (<i>Vancouver, BC</i>) (<i>Abstract #2445</i>)	
<u>Liver Transplant Session</u>		<i>Plain of Six Glaciers Room</i>
<i>Chairs: Dr. Denis Marleau</i>		
0800-0900	NASH and Liver Transplantation – Dr. Jim Ellsmere (<i>Halifax, NS</i>)	
0900-1000	Oral Presentations	
0900	Predictors Of Length of ICU Stay and Mortality After Liver Transplant – Sinziana Dumitra (<i>Montréal, QC</i>) (<i>Abstract # 2461</i>)	
0910	The Changing Donor Characteristics in Liver Transplantation over the Last 10 Years in Canada – Nathalie Sela (<i>London, ON</i>) (<i>Abstract # 2439</i>)	
0920	Weight Gain After Orthotopic Liver Transplantation: Is NASH Cirrhosis A Risk Factor For Greater Weight Gain? - Agnès Rakel (<i>Montréal, QC</i>) (<i>Abstract # 2447</i>)	
0930	Total Tumor Volume/Alpha Fetoprotein Score For The Selection Of Liver Transplant Candidate With Hepatocellular Carcinoma; Aprospective Validation – Norm Kneteman (<i>Edmonton, AB</i>) (<i>Abstract # 2479</i>)	
0940	Health-Related Quality Of Life In Long-Term Survivors Of Pediatric Liver Transplantation – Stacey Konidis (<i>Newmarket, ON</i>) (<i>Abstract # 2495</i>)	

	<p>0950 Duct-To-Duct Biliary Anastomosis Yields Similar Outcomes To Roux-En-Y Hepaticojejunostomy In Select Patients Undergoing Liver Transplantation For Primary Sclerosing Cholangitis – Kris Croome (London, ON) (Abstract # 2435)</p>	
1000-1100	COFFEE AMONGST THE POSTERS – Authors Present – (Odd Numbers)	Mount Temple C & Heritage Hall
1100-1130	The Infectious Liver Donor – Dr. Me Linh Luong (Québec)	
1130-1200	The DCD Liver Donor – Dr. David Foley (Wisconsin)	
1200-1230	Ex-Vivo Liver Perfusion/Repair Strategies – Dr. Markus Selzner (Ontario)	
Donation Group Session		Saddleback Room
<i>Chairs: TBD</i>		
0830-0930	Keynote Speaker Predictors of Death after WLST – Dr. Alan Yee	
0930-0945	Abstract Presentation The Development of a Process to Facilitate Contact Between Donor Families and Recipients in Alberta, Canada – Kim Worton (Edmonton, AB) (Abstract # 2510)	
0945-1100	COFFEE AMONGST THE POSTERS – Authors Present – (Odd Numbers)	Heritage Hall
1100-1230	Expanding Possibilities: Building Self-Sufficient Sustainable Hospital Donation Programs When Geography is a Challenge – Cynthia Isenor Is Accreditation the Right Direction? – Dominic Adorno	
1230-1330	Lunch on own	
1230-1330	Women in Transplantation (WIT) Meeting- All Welcome	Pipestone Room
1230-1430	CST Pediatric Research Group Meeting (closed)	Agnes Room
1230-1430	CORR-CIHR Meeting (closed)	Lefroy Room
1330-1430	ETHICS FORUM – Is Substance Abuse a Morally Relevant Criterion for Organ Transplant Decisions? – Dre Suzanne Leclair (Montréal, QC)	Mount Temple A & B
1430-1550	CLINICO-PATHOLOGIC CONFERENCE <i>Chairs: Drs. Michael Mengel and Kathryn Tinckam</i>	Mount Temple A & B
1430-1510	Case 1: The Difficult Donor Clinician: Dr. John Gill, (University of British Columbia) Pathologist: Dr. Alex Magil, (University of British Columbia) <i>Objectives: To critically review the existing scores and risk assessment indexes for donor assessment and organ allocation: their availability and technical performance and limitation, their clinical limitations. To review therapeutic interventions for improving organ quality and recipient performance. To identify absolute contra-indications for accepting a donor organ, if any exist.</i>	
1510-1550	Case 2: AMR – Subclinical AMR, The Known Unknown Clinician: Dr. Peter Nickerson, (University of Manitoba) <i>Objectives: To understand methods of detecting HLA antibodies. To understand significance of de novo DSA. To understand impact of current therapies of de novo DSA.</i> Pathologist: Dr. Ian Gibson, (University of Manitoba) <i>Objectives: To review the risk factors and time course for de novo DSA and AMR. To show the pathological features of AMR in renal allograft biopsies. To show the importance of clinicopathological correlation in renal allograft biopsy interpretation. To describe the relevance of non-compliance, the histological and clinical features associated with de novo DSA and AMR development. To discuss potential management option for non-compliant patients with risk for de novo DSA and AMR.</i>	

1550-1615	Break	Mount Temple C
1600-1700	Adverse Effects of Immunosuppression Working Group (<i>closed</i>)	Mollison Room
1615-1815	<p><u>CST PLENARY SESSION III: Basic and Clinical Science Abstracts</u></p> <p><i>Chairs: Drs. Thomas Mueller and Prosanto Chaudhury</i></p> <p>1615 Recipient Pre-Operative Regulatory T Cell Function: A Predictor Of Acute Kidney Injury After Kidney Transplantation - Minh-Tri Nguyen * (<i>Montréal, QC</i>) (<i>Abstract # 2448</i>)</p> <p>1625 Inferior Survival in Liver Transplant Patients with Hepatocellular Carcinoma Receiving Donation after Cardiac Death Liver Allografts - Kris Croome * (<i>London, ON</i>)(<i>Abstract #2438</i>)</p> <p>1635 Inhibition Of Receptor Interacting Protein 3 (RIP3) Promotes Long Term Renal Allograft Survival – Arthur Lau * (<i>London, ON</i>) (<i>Abstract # 2467</i>)</p> <p>1645 Incidence, Determinants And Management Of Neoplasia After Kidney Transplantation: A Population-Based Study From 1985-2009 – Heloise Cardinal (<i>Montréal, QC</i>) (<i>Abstract # 2437</i>)</p> <p>1655 Rip3 Mediated Necroptosis Regulates Cardiac Allograft Inflammation and Survival – Alexander Pavlosky (<i>London, ON</i>) (<i>Abstract # 2464</i>)</p> <p>1705 Early Success With Initiatives To Increase Deceased Donation In BC – Jagbir Gill (<i>Vancouver, BC</i>) (<i>Abstract # 2488</i>)</p> <p>1715 Subnormothermic Ex Vivo Liver Perfusion (NEVLP) Reduces Ischemia/Reperfusion Injury in Livers Retrieved after Cardiac Death (DCD) – Jan M. Knaak * (<i>Toronto, ON</i>) (<i>Abstract # 2456</i>)</p> <p>1725 An Assessment of the Time-Dependent Effect of Blood Pressure on the Risk of Graft Failure in Kidney Transplant Recipients Using a Marginal Structural Model – Nishant Fozdar * (<i>Toronto, ON</i>) (<i>Abstract # 2486</i>)-<i>presented by Dr. Joseph Kim.</i></p> <p>1735 Endothelin-1 and Big-Endothelin-1 as Potential Biomarkers in Clinical Ex Vivo Lung Perfusion – Tiago Machuca (<i>Toronto, ON</i>) (<i>Abstract 2468</i>)</p> <p>1745 Reduction in New Onset Diabetes After Transplant (NODAT) With Erythropoietin Stimulating Agents, A Case Control Study – Jeffrey Zaltzman (<i>Toronto, ON</i>) (<i>Abstract # 2421</i>)</p> <p>1755 Expansion of CD25+FOXP3+ regulatory T cells from pediatric thymic tissue: potential for cellular therapy? – Esmé Dijke (<i>Edmonton, AB</i>) (<i>Abstract # 2491</i>)</p> <p>1805 Going with the Flow, Canadian Crossmatch Standardization - Robert Liwski (<i>Halifax, NS</i>) (<i>Abstracts # 2457 and 2459</i>)</p> <p><i>*denotes a CST Trainee Award Winner 2013</i></p>	Mount Temple A & B
1815-1830	BREAK- Cheese and Fruit- Cash Wine Bar	Heritage hall
1830-2000	<p>1830-1915 - CST ANNUAL GENERAL MEETING & ELECTION</p> <p>1915-1930 – CNTRP Presentation</p> <p>1930-1945 - CORR ANNUAL GENERAL MEETING</p> <p>1945-2000 - CBS REPORT</p>	<p>Mount Temple A & B</p> <p>Mount Temple A & B</p> <p>Mount Temple A & B</p> <p>Mount Temple A & B</p>
2030-2230	<p>PRESIDENT'S DINNER (Invitation only)</p> <p>FREE EVENING</p>	Alpine Room

SATURDAY, MARCH 16 / LE SAMEDI 16 MARS 2013

0600-1000	REGISTRATION – INSCRIPTION	Alpine Gallery
0630-0745	SUNRISE SYMPOSIUM 0630-0700 Breakfast 0700-0745 Symposium – DSA Conundrums Pre and Post-Transplant <i>Chair: Dr. Patricia Campbell</i> Understanding and Trusting the Virtual XM – Dr. Anat Tambur (Chicago, IL) <i>Objectives: To understand the strengths and options for utilizing the VXM in allocation and risk assessment; to describe the limitations of virtual XM versus actual XM; to understand why virtual XM continues to evolve in complexity.</i> Post Tx DSA: To Screen or Not to Screen – Dr. Peter Nickerson (Winnipeg, MB) <i>Objectives: To review the prevalence and consequence of post Tx DSA in SOT. To discuss recommended post-transplant screening strategies for determining interventions. To discuss treatment options for patients who develop post-transplant DSA.</i>	Mount Temple A & B
0700-1000	SET-UP POSTERS (Even numbers)	Heritage Hall
0700-1200	EXHIBITS CONTINUE	Mount Temple C
0800-1200	<u>CST PLENARY SESSION IV - BASIC and CLINICAL PLENARY : “From Bench To Bedside – Research to Reality”</u> <i>Chairs: Drs. Joe Kim and Steven Paraskevas</i> <i>A focus on scientific developments at various stages in the bench to bedside process with emphasis on the steps/challenges to move discoveries from the lab/research setting into the clinic.</i> 0800-0835 Apoptosis – Dr. Marie-Josée Hébert, (University of Montréal) <i>Objectives: Review mechanisms of cell death and their importance in transplantation. Review the concept of apoptotic secretome and its function. Define the impact of the apoptotic secretome on the humoral response.</i> 0835-0910 CORMs – Dr. Patrick Luke, (University of Western Ontario) 0910-0945 Infectious Diseases Biomarkers – Dr. Deepali Kumar, (University of Alberta)	Mount Temple A & B
0945-1045	COFFEE AMONGST THE POSTERS – Authors Present - (Even Numbers)	Mount Temple C & Heritage Hall
1045-1200	<u>CST PLENARY SESSION IV - BASIC and CLINICAL PLENARY (continued)</u> <i>Chairs: Drs. Joe Kim and Steven Paraskevas</i> 1045-1130 Clinical Use of Cardiac Transplant Biomarkers in Rejection Monitoring – Dr. Hannah Valantine, (Stanford University) <i>Objectives: Review the range of biomarkers available for rejection surveillance. Focus on genomic-based biomarkers. Discuss biomarkers that have been clinically tested: Gene expression profiling and donor DNA.</i> 1130-1200 Panel Discussion: Next Steps in Translation – How Do We Get From Here to There?	Mount Temple A & B
0800-1230	<u>PHARMACIST GROUP SESSION (Open to all Delegates)</u> <i>Chairs: Jennifer Harrison and Christopher Daley</i> 0800-0845 The Transplant Pharmacist: Untangling the Where, What and When – Jennifer Gibson (Winnipeg, MB) 0845-0930 Clinical Pearls in Transplant Psychiatry Dr. Susan Abbey (University Health Network, Toronto, ON)	Plain of Six Glaciers Room

	<p>0945-1045 COFFEE AMONGST THE POSTERS – Authors Present - (Even Numbers)</p> <p>1045-1130 Management of the Drug Interactions in HIV+ and HCV+ Transplant Recipients – A Focus on Protease Inhibitors – Christin Rogers <i>(Beth Israel Deaconess Medical Center, Boston, MA)</i></p> <p>1130-1230 Business Meeting (Pharmacist Group Members Only) (closed)</p>	Heritage Hall														
1230-1600	<p><u>ALLIED HEALTH SESSION</u></p> <p><i>Chairs: Jenny Wichart and Janet Madill</i></p> <p>1230-1300 Networking and Lunch</p> <p>1300-1400 Business Meeting</p> <p>1400-1600 Education Session: Communication Strategies that Enhance Care: When Conversations Matter the Most – Michele Durrant <i>(Toronto, ON)</i></p>	Beehive/Lakeshore														
1225-1630	<p><u>CRITICAL CARE SYMPOSIUM - The Other Patient: Donor’s Perspective from the Critical Care Community</u></p> <p><i>Chair: Sandra Cockfield and Prosanto Chaudhury</i></p> <p>(A plated lunch will be served to participants who have registered to the Symposium on their overall conference registration form)</p> <p><i>Session Objectives: To discuss deceased-donor specific clinical and research topics of importance in donation and transplantation. To improve communication and collaboration between the critical care/donation and transplant community. To establish opportunities between critical care and transplant to improve donor performance.</i></p> <p>1225-1230 Introduction</p> <p>1230-1300 Canada-WHO International Determination of Death Guidelines and Depict Prospective Study of Auto Resuscitation and Vital Signs After Cardiac Arrest - Dr. Sam Shemie</p> <p>1300-1515 Donation Performance In Canada: Problems and Potential Solutions</p> <table border="1" data-bbox="609 997 1344 1417"> <tr> <td colspan="2"><u>DCD –A Missing Priority in Canadian Donation and Transplant</u></td> </tr> <tr> <td>1300-1330</td> <td>The Role of Critical Care in DCD in Canada - Dr. Michael Sharpe</td> </tr> <tr> <td>1330-1400</td> <td>DCD Outcomes in Canada - Dr. Jeff Zaltzman</td> </tr> <tr> <td>1400-1415</td> <td>Break</td> </tr> <tr> <td colspan="2"><u>The Rise and Rise of Controlled DCD: How the UK Overcame the Ethical, Legal and Professional Obstacles</u></td> </tr> <tr> <td>1415-1445</td> <td>DCD Donor Management in the UK – The Prescription For Improved Performance - Dr. Dale Gardiner</td> </tr> <tr> <td>1445-1515</td> <td>Intensivist Lead Donation - Dr. Dale Gardiner</td> </tr> </table> <p>1515-1600 Donation , Critical Care and Transplant In Canada: Steps Forward – Dr. Stephen Beed</p> <p>1600-1630 Panel Discussion</p>	<u>DCD –A Missing Priority in Canadian Donation and Transplant</u>		1300-1330	The Role of Critical Care in DCD in Canada - Dr. Michael Sharpe	1330-1400	DCD Outcomes in Canada - Dr. Jeff Zaltzman	1400-1415	Break	<u>The Rise and Rise of Controlled DCD: How the UK Overcame the Ethical, Legal and Professional Obstacles</u>		1415-1445	DCD Donor Management in the UK – The Prescription For Improved Performance - Dr. Dale Gardiner	1445-1515	Intensivist Lead Donation - Dr. Dale Gardiner	Mount Temple A & B
<u>DCD –A Missing Priority in Canadian Donation and Transplant</u>																
1300-1330	The Role of Critical Care in DCD in Canada - Dr. Michael Sharpe															
1330-1400	DCD Outcomes in Canada - Dr. Jeff Zaltzman															
1400-1415	Break															
<u>The Rise and Rise of Controlled DCD: How the UK Overcame the Ethical, Legal and Professional Obstacles</u>																
1415-1445	DCD Donor Management in the UK – The Prescription For Improved Performance - Dr. Dale Gardiner															
1445-1515	Intensivist Lead Donation - Dr. Dale Gardiner															
1645-1800	<p><u>CST PLENARY SESSION – DEBATE: Be It Resolved That: We Should Increase Organ Supply by Using High Infectious Risk Donors</u></p> <p><i>Chair: Dr. Anthony Jevnikar</i></p> <table border="1" data-bbox="389 1648 1344 1795"> <tr> <td>Pro: “We Should Be Using High Infectious Risk Donors” – Dr. Atul Humar, <i>(University of Alberta)</i></td> </tr> <tr> <td>Con: “Some Donors Are Higher Risk Than Others –We Shouldn’t Use Them” – Dr. Edward Cole, <i>(University of Toronto)</i></td> </tr> </table>	Pro: “We Should Be Using High Infectious Risk Donors” – Dr. Atul Humar, <i>(University of Alberta)</i>	Con: “Some Donors Are Higher Risk Than Others –We Shouldn’t Use Them” – Dr. Edward Cole, <i>(University of Toronto)</i>	Mount Temple A & B												
Pro: “We Should Be Using High Infectious Risk Donors” – Dr. Atul Humar, <i>(University of Alberta)</i>																
Con: “Some Donors Are Higher Risk Than Others –We Shouldn’t Use Them” – Dr. Edward Cole, <i>(University of Toronto)</i>																
1900-ON	<p>ANNUAL DINNER AND AWARDS</p> <p>Ticketed Dinner</p>	Victoria Ballroom														

SUNDAY, MARCH 17 / LE DIMANCHE 17 MARS 2013

0800-0930 Breakfast Meeting of CST 2013-2015 Board (Closed)

This event is an accredited group learning activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of General Surgeons.
La présente activité est approuvée par l'Association canadienne des chirurgiens généraux et constitue une activité de formation collective agréée conformément à la définition précisée dans le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

CST EXECUTIVE - 2012-2013 - BUREAU DE DIRECTION DE LA SCT

President, Dr. Tom Blydt-Hansen
Past President, Dr. Marcelo Cantarovich
Vice-President, Dr. Steven Paraskevas
Treasurer, Dr. David Grant
Member at Large, Dr. Ian Alwayn
Member at Large, Dr. Atul Humar

Member at Large, Dr. Shaf Keshavjee
Member at Large, Dr. Patrick Luke
Member at Large, Dr. Eberhard Renner
Member at Large, Dr. Jean Tchervenkov
Member at Large, Associate Member, Ms. Alison Drabble

CST COUNCIL - 2012 - / CONSEIL DE LA SCT

Chair, Dr. Debra Isaac
Dr. Trish Campbell
Ms. Jennifer Harrison
Dr. Bryce Kiberd
Mr. Ed Ferre

Dr. Dale Lien
Dr. Jeffrey Schiff
Dr. Véronique Phan
Dr. Denis Marleau
Ms. Jenny Wichart

CST SCIENTIFIC MEETINGS COMMITTEE - 2012 - 2013 - COMITÉ DES RÉUNIONS SCIENTIFIQUES DE LA SCT

Chair, Kathryn Tinckam
Co-Chair, Deepali Kumar
Past Chair, John Gill
Ian Alwayn
Lorraine Bell
Jean-François Cailhier
Prosanto Chaudhury

Anson Cheung
Christopher Daley
Sacha de Serres
Edward Ferre
Tammy Keough-Ryan
Dale Lien
Janet Madill

Michael Mengel
Thomas Mueller
Vicky Ng
Michel Pâquet
Markus Selzner
Leroy Storsley
Simon Urschel